Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MEI Pharma, Inc.

< Previous 1 2 Next >
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Results of Special Meeting of Stockholders
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Responds to Anson and Cable Car
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Postpones Special Meeting of Shareholders
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Responds to Anson and Cable Car
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Board of Directors Rejects Unsolicited Proposal
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces 1-for-20 Reverse Stock Split
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
From MEI Pharma, Inc.
Via Business Wire
Tickers INFI MEIP
MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Initiates Strategic Realignment
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.